Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lamisil AT Spray Pump, Solution Dropper Line Extensions Launching June 1

This article was originally published in The Tan Sheet

Executive Summary

Novartis Lamisil AT Spray Pump and Solution Dropper, both terbinafine hydrochloride solution 1%, are launching June 1, "just in time for the peak summer athlete's foot season," the firm said. FDA approved the Rx-to-OTC switch March 17. Novartis filed the NDA (21-124) for the topical solution with the agency May 14, 1999.
Advertisement

Related Content

Lotrimin Ultra Antifungal Switch Approved By FDA
Lotrimin Ultra Antifungal Switch Approved By FDA
Lotrimin Ultra Antifungal Switch Approved By FDA
Schering-Plough Foot Care Sales Show Modest Growth; Sun Care Plummets
Schering-Plough Foot Care Sales Show Modest Growth; Sun Care Plummets
Novartis
NBA going "toe-to-toe" with athlete's foot
Novartis Launching Lamisil AT With $20 Mil. TV/Print Ad Campaign
Novartis Lamisil AT OTC Antifungal Said To Work In One Week
Novartis Lamisil AT OTC Antifungal Said To Work In One Week

Topics

Advertisement
UsernamePublicRestriction

Register

PS091015

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel